Danish enzyme producers Chr. Hansen and Novozymes have entered into an agreement to merge, with the aim of creating a global leader in biosolutions.
Chr. Hansen develops ingredients for the food, pharmaceutical and agricultural industries, including cultures, enzymes and probiotics, while Novozymes describes itself as “the world’s largest provider of enzyme and microbial technologies”.
Ester Baiget, president and CEO of Novozymes, said: “The combination of two strategically complementary companies with a shared purpose and advanced capabilities will show the world the true power of biosolutions”.
She added: “Novozymes and Chr. Hansen share the strong conviction that our combined scale, know-how, commercial strengths and innovation excellence will drive value for our shareholders, customers and society at large by providing the sustainable solutions the world so urgently needs”.
Offering a broad “biological toolbox,” the combined company is expected to have annual revenue of approximately €3.5 billion. With around 10,000 employees, the biosolutions group will operate a global network of 23 manufacturing sites and 38 R&D and application centres.
Novo Holdings is the largest shareholder in both Novozymes and Chr. Hansen. Chairman Lars Rebien Sørensen said: “The two companies are a perfect match. Chr. Hansen with its expertise in microbials and Novozymes with its background in enzymes.”
Upon completion of the merger, Baiget will assume leadership of the combined group as CEO, while Novozymes’ current finance chief, Lars Green, will be CFO.
The merger is contingent on approvals via extraordinary general meetings of the two companies, as well as regulatory approvals. The deal is currently expected to be completed in the fourth quarter of next year or first quarter of 2024.
By Antonia Garrett Peel
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.